The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects

OncoImmunology

Volumn 1, Issue 3, 2012, Pages 377-379

  West, Alison C ^a   Christiansen, Ailsa J ^b   Smyth, Mark J ^a,c   Johnstone, Ricky W ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anticancer immunity; Anticancer therapy; Apoptosis; Epigenetic regulatory agent; Hdaci; Immune stimulating antibodies; Immunogenic cell death; Vorinostat

Indexed keywords

CD137 MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; HISTONE DEACETYLASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; PANOBINOSTAT; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; COLON CARCINOMA; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; UPREGULATION;

EID: 84886945318     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.18804     Document Type: Article

References (10)

1. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280:125-33.
2. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006; 12:693-8.
3. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone RW. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009; 114:380-93.
4. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104:8071-6.
5. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84.
6. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008; 57:647-54.
7. Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, et al. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 2008; 123:218-27.
8. Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ, et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci USA 2011; 108:4141-6.
9. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14:364-75, http://dx.doi.org/10.1007/s10495-008-0303-9
10. Sonnemann J, Gressmann S, Becker S, Wittig S, Schmudde M, Beck JF. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol 2010; 66:611-6. http://dx.doi.org/10.1007/s00280-010-1302-4